Can-Fite Biopharma Ltd. has entered into an agreement with Collaborations Pharmaceuticals Inc. (CPI) to develop anticancer drugs utilizing artificial intelligence (AI) and machine learning (ML) techniques.

Phasev Inc. has raised $15 million in a funding round that will allow the company to further develop its machine learning (ML) technology that aims to revolutionize clinical trial design, execution and analysis. The funding round was led by Viola Ventures and Exor Ventures and included participation from Lionbird and a group of prominent angel investors.

Artificial intelligence (AI) is in full development, and advances are already used in many fields, including medicine. In oncology, these tools can identify a tumor in an image with 99% accuracy. But they can also miss it if the algorithm was not developed with the right data or the correct decisions. The 2023 European Society for Medical Oncology (ESMO) Congress brought together in Madrid doctors and deep learning experts to discuss the challenges and advances of AI in this area. And what’s better than asking an AI what its trainer has told it about AI?

Geethanjali Radhakrishnan, founder and managing director of Chennai, India-based Adiuvo Diagnostics Pvt. Ltd. reported filing for patent protection for a digital assistant for wound triaging and treatment recommendations.

Biomap (Beijing) Intelligent Technology Co Ltd. has entered into a strategic collaboration with Sanofi SA to co-develop cutting-edge artificial intelligence (AI) modules for biotherapeutic drug discovery by leveraging Biomap’s AI platform.

Quris Technologies Ltd. (Quris-AI) and Merck KGaA have extended their collaboration after a successful initial preclinical study of Quris-AI’s BioAI drug safety platform.

Deep Genomics Inc. has introduced its artificial intelligence (AI) foundation model for RNA, BigRNA, which enables discovery of disease mechanisms and candidate therapeutics.

Replay Holdings LLC has announced a research collaboration between Jura Bio Inc. and Syena, a cell therapy product company launched by Replay and the University of Texas MD Anderson Cancer Center earlier this year, to develop T-cell receptor (TCR)-based therapies.